Letters to the Editor
Ankylosing Spondylitis and Spinal Osteotomy From Mr W. Alexander Law The London Hospital, Whitechapel, London El Dear Sir, Thank you for letting me see a copy of Dr Dixon's letter (January Proceedings, p 53) concerning my paper in the October issue (p 715 (October Proceedings, , and the subsequent correspondence (December, p 950), I feel that every contributor has painted an excessively dismal picture of the prognosis of these conditions. In my own series I have yet to lose a single patient from the sequelh of malignant disease of the mouth, except where the tumour was so advanced at initial presentation that it was considered inoperable (i.e. tumours of more than 4 cm minimum diameter, or with widespread metastases).
From my discussions with other colleagues working in this field, it would seem that my results are in no way unusual. The crude radiotherapy figures at Torbay are: after one year, 42 cases, 5 known dead and 3 failed follow up; after two years, 31 cases, 6 known dead and 3 failed follow up. These cases include all malignant tumours of lip, mouth, palate, jaws, anterior two-thirds of tongue and posterior third of tongue. They also include those cases considered inoperable at first presentation. This shows a one-year survival rate of more than 80 %, and possibly as high as 87 %, and a two-year survival rate of at least 66 % and possibly 80 Project Selection in the Pharmaceutical Industry From Professor H C Stewart Northwood, Middlesex Dear Sir, I was interested to read the report in the Proceedings (December, pp 885-894) of the meeting of the Medico-Pharmaceutical Forum (2 June 1976) on the subject of project selection in the pharmaceutical industry.
The problems facing the pharmaceutical industry in this country are formidable at the present time, and it was generally helpful that the industry was able to state its case and that some opposite views were aired also. Having been head of a pharmacology department in the University of London for about 25 years and, during the same period, advised a number of pharmaceutical companies, I find it difficult to disagree strongly with any thing that was said. However, as far as this country is concerned the 'project selection in the drug treatment of disease' in its widest sense is a difficult and complicated problem, which involves much more than the pharmaceutical industry, though they of course play the major part.
Pharmacology in this country was the Cinderella of experimental subjects for a very long time and in many places it still is. In the last century, it was taught in the universities, almost without excep-
